By contrast, other typically prescribed first-line AIDS medicines are priced $3,000 to $5,400 less. Moreover, BMS has improved the price of Reyataz year over calendar year; since it was approved in 2003 first, the price of Reyataz has elevated by over 25 percent. AHF officials note that Reyataz must be used with at least two various other HIV/AIDS drugs as part of an effective antiretroviral treatment regimen. ‘By prices Reyataz up to two and a half times more than other AIDS medications, Bristol Myers Squibb is certainly putting greed above people’s lives,’ said Michael Weinstein, AIDS Healthcare Basis President, in a declaration. ‘At $13,000 per patient each year, it is the expense of medications like Reyataz that threatens to bankrupt condition programs like ADAP, harming the sufferers who rely on such programs for the lifesaving medications they want.Remember to speak to your doctor about a comprehensive approach to malignancy treatment and how to make use of naturopathic and choice cancer treatments to obtain additional out of your health care services and to provide your body a better fighting chance.. 15 percent of Asians surviving in NEW YORK are chronically infected with hepatitis B virus Around 15 percent of Asians surviving in NEW YORK are chronically infected with hepatitis B virus, according to a fresh study by NY University School of Medicine researchers and their colleagues. Chronic hepatitis B an infection usually will lead to liver inflammation and may progress to cirrhosis and liver cancer. The reported infection price is 35 times greater than the rate in the overall U.S.